A Study of Fabrazyme in Pediatric Patients With Fabry Disease

Inclusion criteria: * Patient or legal guardian must provide written informed consent * Patients must have a clinical diagnosis of Fabry disease and active Fabry disease (clinical signs and symptoms) * Patients must be at least 7 years of age but no older than 15 years of age at time of enrollment * Patients must be Tanner Stage ≤ III * Female patients must have a negative pregnancy test prior to each infusion and use a medically accepted form of contraception throughout the study Exclusion Criteria: * Patient has a clinically significant organic disease (with the exception of symptoms relating to Fabry disease) that in the opinion of the investigator would preclude participation in the trial * Patient has participated in a study employing investigational drug within 30 days of the start of this study * Patient has received prior treatment with enzyme replacement therapy * Patient is unable to comply with the clinical protocol